Care program using glucose monitors for newly diagnosed children with type 1 diabetes
Studies a diabetes care program with glucose monitors in newly diagnosed children.
Key facts
- Who runs it
- Stanford University
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Registry title
- 4T Sustainability Program
- Status
- Enrolling by invitation
- People taking part
- 5,000 people, planned
- Started
- 30 May 2024
- Expected to end
- 31 Jan 2028
- Type of study
- Observational
- Treatments tested
- CGM and RPM
- Record updated
- 21 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with type 1 diabetes who are seen at the Stanford Children's Diabetes Clinic. They must agree to wear a CGM with remote monitoring.
- Age
- 6 months to under 21 years
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes: new-onset, or existing type 1 diabetes in those who wear a CGM or want to start one.
Main reasons for not taking part
- A diabetes diagnosis other than type 1 diabetes
- Plans to get diabetes care at another clinic
- Does not agree to CGM use, CGM data integration or remote monitoring
- Older than 21 years
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- All individuals with a T1D diagnosis seen at the Stanford Children's Diabetes Clinic
- Individuals who plan to receive follow-up care at the Stanford Children's Diabetes Clinic
- Individuals who agree to wear a CGM that will connect to the RPM-care model
- Age: six months to < 21 years of age
- Patient or guardian must own and operate a compatible smart device/phone to send data from the CGM into the HIPAA-compliant RPM-care model for data analysis and review by a care team member; Dr. Maahs and Pediatric Endocrinology have philanthropic funds available to purchase compatible smart devices for participants who do not have a compatible smart device/phone
Who cannot take part
- Diabetes diagnosis other than T1D
- Individuals with the intention of obtaining diabetes care at another clinic
- Individuals > 21 years of age
- Individuals who do not consent to CGM use, CGM data integration, remote monitoring
Where in United States
- Lucile Packard Children's HospitalPalo Alto, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The goal of the 4T program is to implement proven methods and emerging diabetes technology into clinical practice to sustain tight glucose control from the onset of type 1 diabetes (T1D) and optimize patient-reported and psychosocial outcomes. The investigators will expand the 4T (Teamwork, Targets, Technology, and Tight Control) program to all patients seen at Stanford Pediatric Diabetes Endocrinology as the standard of care. Disseminating the 4T program as the standard of care will optimize the benefits of diabetes technology by lowering HbA1c, improving PROs, and reducing disparities.
The group in the trial
- Standard of Care - CGM and RPM
1\. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
Treatment: CGM and RPM
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D: 4T Sustainability Program.
- Plain-language title
- Care program using glucose monitors for newly diagnosed children with type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 May 2025